Cell based assays 3d cell culture

1. 1
ATTA
Cell Based Assays 2012
26th -27th June 2012 London, UK
Cell Based Assays Conference is a much awaited symposium where latest
developments on cell based assays and their significance to the strategic
future of Research and Development in pharmaceutical industry will be
discussed and debated. Here in Cell Based Assays Conference keynote
speakers like Eberhard Krausz, Marianthi Papakosta, Marie H. Delmotte,
Dr. Peter Horvath, Professor Marc Bickle etc will come and provide latest
updates on cell based assays. Plenary sessions, debates and discussions
will be very much beneficial
Who should attend this event?
Heads of Department, Directors, Managers, Team Leaders Researchers and
Scientists from:
 Screening
 Pre-clinical Research
 Pharmacology
 Lead discovery technologies
 Molecular and cellular biology
 Biological technologies
 Lead generation and optimization
 High-content analysis
 Target identification and validation
 Target discovery
 In vitro assays
 Compound profiling
 Assay development
1
ATTA

2. Cell Based Assays 2012
26th-27th June 2012, London UK.
Key Speakers
Eberhard Krausz, Director, Assay Development & Target Validation, Enabling Biology, Janssen
Research & Development
Marianthi Papakosta Scientific Director at Grunenthal GmbH
Marie H. Delmotte Lab Head Cellular and Molecular Biology at Novartis
Dr. Jeroen van Bergeijk GPRD Research Neuroscience Molecular Biology & Biochemistry Abbott
GmbH & Co. KG
Dr. Xavier Leroy Project Promoter & Leader Associate Director Drug Discovery Dept. Actelion
Pharmaceuticals Ltd
Thomas Koblizek Senior Scientist R&D Lonza
Dr. Peter Horvath, Head of image and data analysis, ETH Zurich, Light Microscopy Centre.
Marc Bickle Head of Technology Development Studio at Max Planck Institute of Molecular Cell
Biology and Genetics
Remko de Pril Team Leader Target Discovery and High-Content Screening Galapagos
David R. Greaves Professor of Inflammation Biology Sir William Dunn School of Pathology University
of Oxford
Robin Ketteler MRC LMCB University College London
Jens Kelm, PhD, co-founder of InSphero AG
Sponsored by:
InSphero AG Lonza TAP Biosystems
Organized by: ATTA LTD. http://www.attaconference.co.uk

3. Day 1 Cell Based Assays 2012
12:00 Sponsor Speaking section th June 2012
contact
09:00 Registration and refreshments 26
tareef.ahmed@atta-online.co.uk
09:30 Opening address from the Chair 12:40 Networking lunch
09:40 Quantitative analysis of cell-based 13:40 Targeting endogenous stem cells
high-content drug and siRNA screens - for therapy
How can machine intelligence help? Targeting endogenous stem cells for
Image quality enhancement (vignetting) therapy and related approaches (e.g.
Image analysis of end point- and time- IPSCs).
resolved data (segmentation, feature Recruitment of (neuronal) stem and
extraction, tracking) Multi-parametric precursor cells for regeneration &
analysis of single cell-based assays using neuroprotection
machine learning (classification, Targeting cancer stem cells for
regression, method optimization, weakly- oncology
supervised approaches) Hedgehog signaling
Statistical analysis and quality control Dr. Jeroen van Bergeijk GPRD
issues Research Neuroscience Molecular
Dr. Peter Horvath, Head of image and Biology & Biochemistry Abbott GmbH
data analysis, ETH Zurich, Light & Co. KG
Microscopy Centre
14:20 Carcinogenicity risk assessment
10:20 Systematic analysis of complex of Biologics using in vitro cell-based
signal transduction pathways using protein assays
fragment complementation assays Marie H. Delmotte Lab Head -
Protein:protein interactions Classical Cellular and Molecular Biology at
GPCR signaling Non-classical GPCR Novartis
pathways and interconnectivity Examples
for complex networks The PCA working 15:00 Afternoon Refreshments
principle Some PCA examples
Somatostatin homodimers/heterodimer 15:20 Sponsor Speaking section contact
data CXCR4 agonist/antagonist data tareef.ahmed@atta-online.co.uk for more
Thomas Koblizek Senior Scientist R&D detail
Lonza
16:00 Pores for thought; analyses of
11:00 Morning refreshments TRPV1 chimeras using a bespoke heat
activation assay, demonstrate that
11:20 Use of cell based GPCR assays to differences in the pore domain confer
identify novel CB2 agonists and species specific pharmacological
chemokine receptor antagonists sensitivity
David R. Greaves Professor of Marianthi Papakosta Scientific
Inflammation Biology Sir William Director at Grunenthal GmbH
Dunn School of Pathology University of
Oxford 16:40 Closing remarks from the Chair

4. Day 2 Cell Based Assays 2012
th
27 June 2012
09:00 Registration and refreshments 12:40 Networking lunch
09:30 Opening address from the Chair 13:40 plate based screening
Gene expression assay
09:40 Primary cells and 3D models in Label-free as well as assay
high-throughput screening development native neuronal cell types
Robin Ketteler MRC LMCB University Presentation from Pfizer
College London
2:00 Sponsor Speaking section contact
10:20 Polarity markers as functional tareef.ahmed@atta-online.co.uk for more
readouts of hepatic toxicity in 3D detail
use of bacterial artificial chromosome to
ensure physiological levels of tpj1-cherry 14:20 Beta-Arrestin 2 in Drug
polarity marker expression 3 dimensional Discovery
cell culture to ensure polarity and Deorphanisation
functional bile canaliculi system HTS
generation of transgenic animals for Biased signaling
primary cell culture high throughput Scavanger
imaging of live polarised hepatocytes In-vitro to in-vivo
automated image analysis Xavier Leroy, Ph.D. Project Promoter
Marc Bickle Head of Technology & Leader Associate Director Drug
Development Studio at Max Planck Discovery Dept. Actelion
Institute of Molecular Cell Biology and Pharmaceuticals Ltd
Genetics 15:00 Afternoon Refreshments
11:00 Morning refreshments 15:20 Sponsor Speaking section contact
tareef.ahmed@atta-online.co.uk for more
11:20 Application of in vitro 3D models detail
for drug discovery
More complex and therefore 16:00 High-Content screen for
physiologically more relevant cell-based inhibitors of cell migration in cancer
assays will ultimately be more predictive metastasis using adenoviral knock-
than current 2D-based assays. down, high-throughput wound healing
Technologies and assay set-up for assay which we developed to identify
medium-throughput compound screening novel genes involved in metastatic cell
in 3D (co-) cultures migration. Genes whose knock-down
High-content analysis is a versatile inhibit cell migration were identified
technology platform to capture complex by their effect on the open wound
cell-based assays. Remko de Pril Galapagos Team
Applications in oncology, virology and Leader Target Discovery and High-
safety pharmacology Content Screening
16:40 Closing remarks from the Chair
Eberhard Krausz, Director, Assay
Development & Target Validation, 16:50 End of the conference
Enabling Biology, Janssen Research &
Development, Belgium
12:00 3D Microtissues for Early
Compound De-Risking
Jens Kelm, PhD, co-founder of InSphero
AG

5. Registration Form for Cell Based Assays 2012
26th -27th June 2012, London UK.
DELEGATE DETAILS
Please complete fully and clearly in capital letters and e-mail it to
tareef.ahmed@atta-online.co.uk
Please photocopy for additional delegates.
Price: £499
Title:
Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature:
Date:
I agree to be bound by ATTA’s Terms and Conditions of Booking.
Payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and
prior to the start of the event. If payment has not been received then credit card details will be requested and payment
taken before entry to the event. Bookings within 7 days of event require payment on booking. Access to the Document
Portal will not be given until payment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate to take your
place at any time prior to the start of the event. Two or more delegates may not ‘share’ a place at an event. Please make
separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will
refund/credit 50% of the due fee less a £50 administration charge,
providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regretfully
cancellation after this time cannot be accepted. We will however provide the conferences documentation via the
Document Portal to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the
Briefings we are not normally able to provide documentation in these circumstances. We cannot accept cancellations of
orders placed for Documentation or the Document Portal as these are reproduced specifically to order. If we have to
cancel the event for any reason, then we will make a full refund immediately, but disclaim any further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the
event compared to the advertised programme